Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871952 | 0.90 | PRKCI (0.39) | CYP2A6MIFPRKCI | |
| SCHEMBL13872211 | 0.86 | CYP2A6 (0.35) | CYP2A6EGFRIDO1TDO2PRKCI | |
| SCHEMBL13872271 | 0.86 | PRKCI (0.43) | CYP2A6EGFRIDO1TDO2PRKCI | |
| SCHEMBL13113707 | 0.85 | NPC1 (0.37) | CYP2A6MIFLPAR5 | |
| SCHEMBL13871967 | 0.83 | HTR6 (0.43) | EGFRIDO1TDO2 | |
| SCHEMBL13871946 | 0.83 | IDO1 (0.38) | CYP2A6EGFRIDO1TDO2LPAR5 | |
| SCHEMBL13871896 | 0.83 | HTR7 (0.37) | CYP2A6EGFRIDO1TDO2 | |
| SCHEMBL13871957 | 0.82 | HTR6 (0.39) | CYP2A6EGFRIDO1TDO2LPAR5 | |
| SCHEMBL14818581 | 0.80 | PTK2 (0.33) | CYP2A6 | |
| SCHEMBL13871897 | 0.80 | OXER1 (0.33) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009042907-A1 | ISOINDOLINE COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-04-02 | — | — | WO | disclosed |